Calidi Biotherapeutics Earnings Estimate

CLDI Stock   0.82  0.01  1.20%   
By analyzing Calidi Biotherapeutics' earnings estimates, investors can diagnose different trends across Calidi Biotherapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Calidi Biotherapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Calidi Biotherapeutics is projected to generate -1.860075 in earnings per share on the 31st of December 2025. Calidi Biotherapeutics earnings estimates show analyst consensus about projected Calidi Biotherapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Calidi Biotherapeutics' historical volatility. Many public companies, such as Calidi Biotherapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Calidi Biotherapeutics' earnings estimates, investors can diagnose different trends across Calidi Biotherapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. The Calidi Biotherapeutics' current Gross Profit is estimated to increase to about (1.3 M). The Calidi Biotherapeutics' current Pretax Profit Margin is estimated to increase to -617.04Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calidi Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.

Calidi Biotherapeutics Earnings per Share Projection vs Actual

About Calidi Biotherapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Calidi Biotherapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Calidi Biotherapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Calidi Biotherapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-109.5 M-115 M
Earnings Yield(2.78)(2.64)
Price Earnings Ratio(0.37)(0.39)
Price Earnings To Growth Ratio 0.01  0.01 

Currently Active Assets on Macroaxis

When determining whether Calidi Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Calidi Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Calidi Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Calidi Biotherapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calidi Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.36
Return On Assets
(1.20)
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.